Dr. Castillo on the Use of Venetoclax in Waldenstrom Macroglobulinemia

Name: Dr. Castillo on the Use of Venetoclax in Waldenstrom Macroglobulinemia
Uploaded: 2019-09-15T23:35:00.000Z
Description: Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.

September 15, 2019

Jorge J. Castillo, MD

Video

Conference|International Myeloma Society Annual Meeting

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.

<<< 17th International Myeloma Workshop